Lonza Bioconjugate Services
ADCs / bioconjugates pose a complex challenge from a development and manufacturing perspective. We offer a complete end to end solution that simplifies the value chain and accelerates the timeline to the clinic or the market.
Our full-service offering for bioconjugates/ADCs provides you with:
- Early de-risking and optimization
- Process development and optimization
- Formulation development
- Analytical development
- Targeting agent or carrier protein
- Drug substance manufacture
- Drug product manufacture
- Payload and linker manufacturing
We have a successful track record of marketed bioconjugates, providing support through all stages of the lifecycle from concept to commercialization.
Our experience spans a broad range of technologies including:
- AOC’s (Antibody Oligonucleotide Conjugates)
- Antibodies conjugated to nanoparticles (TNPs) and non-cytotoxic drugs (including peptides and polymers
- Conjugated duobodies
- Radio-immunoconjugates (mAb conjugated to chelating agents)
- Vaccines (haptens conjugated to carrier proteins)
- PEGylation and cross-linking
The rapid emergence of novel bioconjugation technologies provides exciting opportunities for enhanced therapeutic profiles, but also renders the development and manufacturing of bioconjugates increasingly complex.
Lonza offers early-development services to assist customers with tailoring bioconjugate development specifically to therapeutic needs and to streamline process development and manufacturing. Customers benefit from an integrated platform combining selected state-of-the-art bioconjugation technologies, drug-linker synthesis, and protein expression with over a decade of experience in the manufacturing of clinical and commercial bioconjugates.
Key attributes of our services are early de-risking and optimization of your protein scaffold, and a toolbox of robust and scalable bioconjugation technologies that will ensure a seamless transition to clinical and commercial manufacturing.
Establishing high quality, commercially viable processes, spanning from pre-clinical development through commercial scale manufacturing.
300+ GMP Batches per Year
GMP batches manufactured at different scales for clinical and commecial supply. The majority of the commercial ADC’ss are produced at Lonza.
Lonza entered the bioconjugates market in 2006 with a focus on Antibody Drug Conjugates (ADC). Our portfolio has further extended over time from ADC’s into different non-cytotoxic bioconjugates.